PCOS and Hormonal Balance: How Peptide and Hormone Therapy Can Help

Polycystic ovary syndrome affects an estimated 8–13% of reproductive-age women, and a substantial share of cases go undiagnosed for years. It is worth being precise about what it is, because the name is misleading: PCOS is an endocrine and metabolic condition, and the ovarian cysts that give it its name are neither required for diagnosis nor the source of the symptoms.

How PCOS Is Actually Diagnosed

The Rotterdam Criteria

Diagnosis requires two of the following three, with other causes excluded:

• Ovulatory dysfunction — irregular or absent periods
• Clinical or biochemical hyperandrogenism — hirsutism, acne, androgenic alopecia, or elevated androgens on labs
• Polycystic ovarian morphology on ultrasound

Because only two of three are needed, a woman can have PCOS with entirely normal-appearing ovaries. This is the most common reason a diagnosis is missed.

Phenotypes Differ Substantially

The combination a patient presents with materially changes the clinical picture. Someone with hyperandrogenism and ovulatory dysfunction has a different metabolic risk profile than someone with ovulatory dysfunction and polycystic morphology but normal androgens. Treatment that ignores the phenotype tends to disappoint.

The Insulin Resistance Engine

Why It Is Central

A majority of women with PCOS have insulin resistance, and it is present in lean patients as well as those with higher BMI. The mechanism is self-reinforcing: elevated insulin stimulates ovarian theca cells to produce androgens, and simultaneously suppresses hepatic production of sex hormone-binding globulin. Less SHBG means more free, biologically active testosterone.

The result is a loop — insulin resistance drives androgen excess, and androgen excess worsens central adiposity and insulin resistance.

Why This Matters for Treatment Selection

Interventions that improve insulin sensitivity tend to improve androgenic symptoms and cycle regularity indirectly, because they interrupt the loop at its source. Interventions that only block androgen effects manage symptoms without addressing the driver. Both have a place; they are not equivalent.

Approaches Used in Practice

This section describes what is used clinically. It is educational, not a treatment plan — PCOS management requires a diagnosing provider.

Insulin-Sensitizing Approaches

Metformin remains the most widely used insulin-sensitizing agent in PCOS, with a long evidence base for effects on cycle regularity and metabolic markers.

Inositols, particularly myo-inositol and D-chiro-inositol, are used as a supplement approach. The 40:1 ratio is common because it approximates the physiological ratio in serum. Evidence is more modest than for metformin but tolerability is generally better.

GLP-1 Receptor Agonists

GLP-1 agonists have become a significant option where weight and metabolic dysfunction are prominent, given their effects on weight and glycemic control. Reported downstream effects on cycle regularity generally follow the metabolic improvement rather than representing a direct ovarian action.

An important practical point: improving insulin sensitivity and losing weight can restore ovulation. Patients who were not previously ovulating and are not seeking pregnancy need contraceptive counselling, because fertility can return unexpectedly. GLP-1 agonists are also generally discontinued before conception, which requires planning.

Anti-Androgen Approaches

Spironolactone is commonly used for hirsutism and androgenic acne. Compounded topical preparations are used for androgenic alopecia and acne where systemic exposure is undesirable — our overview of topical compounding for hair loss and skin covers those formats.

Cycle Regulation

Cyclic or continuous progesterone is used to protect the endometrium in patients with prolonged anovulation, where unopposed estrogen exposure carries a real hyperplasia risk. Compounded progesterone preparations allow non-standard dosing where commercial strengths do not fit.

Where Peptides Fit — Honestly

There is no peptide with a PCOS indication, and the evidence base for peptide therapy in PCOS specifically is thin. What exists is indirect: peptides studied for metabolic and body-composition endpoints address insulin resistance and central adiposity, which are the drivers.

5-Amino-1MQ, studied for adipocyte metabolism through NNMT inhibition, and growth hormone secretagogues studied for body composition are sometimes discussed in this context. Both are preclinical or extrapolated with respect to PCOS. Presenting them as PCOS treatments would overstate what is known.

The Long-Term View

PCOS is associated with elevated long-term risk for type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease, and — where prolonged anovulation goes unaddressed — endometrial hyperplasia. This is why treatment is not purely cosmetic or fertility-driven, and why patients who no longer want children still benefit from metabolic management.

Related reading: Newtropin's women's hormone & peptide therapy program

Frequently Asked Questions

Can you have PCOS without ovarian cysts?

Yes. Diagnosis requires two of three Rotterdam criteria, so a patient with ovulatory dysfunction and hyperandrogenism meets criteria with normal-appearing ovaries. This is a frequent reason diagnosis is delayed.

Is PCOS caused by being overweight?

No. PCOS occurs in lean women as well, and insulin resistance is present across weight categories. Excess weight can worsen the insulin resistance that drives the condition, which makes weight a modifier rather than a cause.

Do GLP-1 medications help PCOS?

They address weight and insulin resistance, which are central drivers, and improvements in cycle regularity are commonly reported downstream. They are not a PCOS-specific treatment, and restored ovulation means contraception needs to be discussed.

What is the difference between metformin and inositol?

Metformin is a prescription medication with the larger evidence base in PCOS. Inositols are supplements with more modest evidence but generally better gastrointestinal tolerability. Some providers use them together.

Does PCOS go away after menopause?

The ovulatory and fertility aspects resolve, but the metabolic profile — insulin resistance and elevated cardiometabolic risk — persists and warrants continued attention.

Can peptide therapy treat PCOS?

No peptide has a PCOS indication, and direct evidence is thin. Peptides studied for metabolic and body-composition endpoints address underlying drivers indirectly. Any use in this context is off-label and requires prescriber judgment.